Summary A serological assay for the quantitative determination of the novel tumour-associated epitope CA242 was developed and used for determination of sensitivity and specificity of CA242 in gastrointestinal cancer. The CA242 assay showed a better tumour specificity than CA50 
Many of the novel monoclonal-antibody defined serological tumour markers, e.g. CA 19-9, CA50, CA125, CA 15-3, MCA, MAM-6, DUPAN-2, TAG-72 belong to the mucinous types of glyco-proteins (Magnani et al., 1983; Lindholm et al., 1983; Bast et al., 1981; Hilkens et al., 1983; Kufe et al., 1983; Stahli et al., 1985; Hilkens et al., 1986; Lan et al., 1987; Johnson et al., 1986) . The mucinous glycoproteins are highly glycosylated high molecular weight substances and may contain many different carbohydrate epitopes with possible tumour specificity. The CA 19-9, CA50 and CA125 assays utilises the same antibody for catching and detecting the antigen (Del Villano et al., 1983; Cooper et al., 1988; Klug et al., 1984) . Careful characterisation of other epitopes on the antigens carrying these epitopes may thus lead to the development of assays with better clinical performance.
The use of tumour marker analyses as a diagnostic aid in the management of cancer patients is an accepted clinical routine in different forms of cancer (International Union Against Cancer 1986) . One disadvantage of existing tumour markers is a relatively low tumour specificity with elevated levels (compared to healthy subjects) commonly found in benign diseases, which limit the use for primary diagnosis of cancer. In order to determine the clinical utility of different tumour markers the Working Group on Tumour Marker Criteria (WGTMC) has concluded that if tumour markers should be used for diagnostic purposes, the reference population used for establishment of cut-off levels should consist of age-matched controls and appropriate benign diseases of the same organ(s) and/or comparable tissues (Bonfrer, 1990) .
Previous papers have demonstrated that different tumourassociated carbohydrate epitopes were co-expressed with CA50 on a mucinous tumour associated antigen named CanAg Johansson et al., 1991b) . One of these novel carbohydrate epitopes, CA242, has, in a preliminary serological evaluation, increased the tumour specificity of assays for detection of the CanAg antigen (Johansson et al., 1991b) .
In this paper, the development of a DelfiaTM assay for the determination of CA242 is described. The clinical utility of the CA242 tumour marker assay further evaluated by determination of tumour sensitivity and specificity in colo-rectal and pancreatic cancer in relation to benign gastro-intestinal disease. The sensitivity and specificity of the CA242 assay is also compared with the established markers CA50, and CEA.
Materials and methods
The C242 MAb and C50 MAb were obtained by immunisation of Balb/c mice with the human adenocarcinoma cell line COLO205 (ATCC) and fusion of splenocytes with Sp 2/0 myeloma cell line (Lindholm et al., 1983 (Lovgren et al., 1984) . The coated plates were stored sealed at + 4°C and were stable for more than 6 months. The C242 MAb was labelled with the Euchelate of isothiocyanatobenzyl-diethylenetriamine-tetraacetic acid to a specific activity of 3-5 Eu/molecule as described (Hemmila et al., 1984 (Sunderman, 1975) . The sensitivity and specificity of the different tumour marker assays were compared by 'Receiver Operated Characteristic' (ROC) analyses (Sunderman, 1975; Metz, 1978) .
The sensitivity and specificity of CA242 and CA50 in CRC Dukes A-D was compared by ROC analyses using patients with ulcerative colitis, adenomas, obstructive biliary disease, other surgical ward patients of similar age as the cancer patients and patients with miscellaneous G-I disease as reference population (the number of patients is given in Table I ). The sensitivity and specificity of CA242 and CA50 in pancreatic cancer were determined using patients with pancreatitis, liver cirrhosis, obstructive biliary disease, miscellaneous G-I disease and other surgical ward patients as reference group. Sensitivity and specificity of CA242 (and CA50) in comparison with CA 19-9 was compared by ROC analyses of results from 81 patients with CRC and 132 patients with benign gastro-intestinal disease. CEA was analysed in 290 patients with CRC (57 Dukes A, 93 Dukes B, 77 Dukes C and 63 Dukes D), 54 cases with pancreatic cancer and in 174 of the patients with benign gastro-intestinal disease.
Results

Analytical performance
The CA242 Delfia assay gave a linear dose-response up to 300 U ml', with a CV% of less than 7% over the whole standard curve range ( Figure 1 ). The inter assay precision showed that t90% of duplicates had a CV% <7.5% and t95% of duplicates had CV% <10% (Table II) . The analytical sensitivity of the assay, defined as the concentra-U 0-U ml-, Figure 1 Dose-response and precision profile of the CA242 Delfia assay. The dose-response and precision profile were based upon determination of standards (and 1/2 and 1/5 dilution of std 5 U ml-') using random pipetting of the standards on one plate. The CV% was calculated from 12 replicates of each standard. 0 CPS; * CV%. tion corresponding to the signal of the 0-standard + 3 s.d.
The reproducibility study showed a total CV% of less than 7% in all but one sample (Table III) Figure 2 . The mean value of CA242 in unselected blood donors and blood donors smoking >20 cig/day was 7.1 ± 5.7 U ml-' and 6.1 ± 4.1 U ml-', respectively, with levels ranging from 1-28 U ml-'. There was no significant difference between smoking and unselected blood donors. Ninety-five per cent of the healthy subjects had CA242 levels below 19Uml-1.
Slightly elevated CA242 levels were found in subjects with 04 The reproducibility was determined by analyses of five serum (sample [1] [2] [3] [4] [5] and five plasma (6-10) samples in replicates of six during 5 days. benign disease. However, the differences between the groups with benign disease and healthy subjects were not statistically significant. In CRC the levels of CA242 correlated with the Dukes stage with highest levels in patients with Dukes C and D. There were no significant differences in CA242 concentration between the group of patients with CRC Dukes A and the patients with benign disease, while the levels in Dukes B, C and D were significantly higher (Table IV, Figure 2 ). Highly elevated levels were also found in patients with other gastrointestinal cancers, particularly pancreatic cancer, but also in subjects with gastric cancer and cholangiocellular carcinomas (Table IV and Figure 2 ). Moderately elevated levels of CA242 were also found in subjects with other pancer diagnoses, Table IV. Sensitivity and specificity of CA242, and comparison with CASO, CA 19-9 and CEA The levels of CA242 were significantly lower than the levels of CA50 in patients with liver cirrhosis (P <0.001), pancreatitis (P <0.05), obstructive biliary disease (P<0.001) and other surgical ward patients (P<0.001), while the CA242 levels were significantly higher in Dukes B (P < 0.1) and in Dukes C and Dukes D (P<0.001) compared to CA50 (Table V) . The ROC analyses of CA242 in CRC in relation to benign gastro-intestinal disease gave at the 90% tumour specificity level a sensitivity of 14%, 30%, 46% and 61% in CRC Dukes A, Dukes B, Dukes C and Dukes D, respectively (Figure 3) . The corresponding sensitivity for CA50 was 4%, 7%, 15% and 44% (Figure 3) . The discriminator level resulting in 90% tumour specificity was 20 U ml-' for CA242 and 45 U ml-' for CA50. In pancreatic cancer the ROC analyses showed a sensitivity of 77% for CA242 and 83% for CA50 at the 90% * @~. The specificity was calculated from analyses of 132 subjects with benign G-I disease, and the sensitivity from analyses of 81 subjects with colo-rectal cancer. * CA242, A CA50, * CA 19-9.
1-specificity tumour specificity level (Figure 4) . A discriminator level of 22 U ml-' and 65 U ml-' for CA242 and CA50 was necessary to obtain 90% tumour specificity. The results of the sensitivity and specificity analyses of CA 19-9, CA242 and CA50 are shown in Figure 5 . Ninety per cent tumour specificity was obtained using a cut-off level of 50 U ml-', 20 U ml -' and 35 U ml1' for CA 19-9, CA242 and CA50, respectively, and the corresponding sensitivity was 23%, 35% and 24%, respectively ( Figure 5 ). The combination of CA242 and CA 19-9 (or CA50) did not increase the sensitivity compared to the use of CA242 alone.
The ROC analyses of CEA and CA242 in 290 cases with CRC, 54 subjects with pancreatic cancer and 174 subjects with benign disease are shown in Figure 6 . The sensitivity in CRC for CEA at 90% tumour specificity was 19%, 40%, 51 % and 71 % in Dukes A, Dukes B, Dukes C and Dukes D, respectively, and for CA242 the corresponding sensitivity was 18%, 29%, 49% and 62%. In pancreatic cancer the sensitivity of CEA was 41 % and 80% for CA242. The combination of CEA and CA242 increased the sensitivity to 28%, 54%, 62% and 79% in Dukes A, Dukes B, Dukes C and Dukes D, while in 9%, 15%, 38% and 52% of the subjects both CEA and CA242 was elevated above the 90% tumour specificity discriminator level (Table VI) . The cut-off levels needed to obtain 90% tumour specificity were 7 ytg 1' for CEA and 22 U ml-' for CA242. The correlation between the CEA and CA242 levels in CRC was low with correlation coefficients ranging from 0.2-0.6 (Figure 7) . 1-specificity ). An additional evidence that CA242 is chemically different from sialylated Lewisa is that the C242 MAb cannot inhibit the binding of anti-sialylated Lewisa antibodies . The CA242 epitope has not been detected in glycolipid extracts Although the same antigen was determined in the CA242 and CA50 assays there were large differences between the levels of the markers in benign gastro-intestinal disease and in CRC. Benign hepato-biliary diseases are known to give elevated levels of CA50 and CA 19-9 (Haglund et al., 1987; Harmenberg et al., 1988; Touitou & Bogdan, 1988) , which was also confirmed in this study. In the CA242 assay slightly elevated levels were found in the patients with hepato-biliary disease, but the levels were significantly lower (P<0.001) than in the CA50 assay. The number of false positive subjects among patients with benign hepato-biliary diseases were not higher than in other groups of benign disease using the CA242 assay, indicating that the specificity of CA242 was similar in hepato-biliary disease as in other benign diseases.
This was in contrast to the CA50 assay, where 39% of patients with liver cirrhosis and 19% of patients with obstructive biliary disease showed levels above the 90% tumour specificity cut-off (45 U ml-'), compared to 1.4% of patients with ulcerative colitis.
The levels of CA242 were not only lower in benign gastrointestinal disease compared to CA50, but in CRC, the CA242 levels were in many cases higher than the CA50 levels. The increased tumour specificity and the higher levels of CA242 in CRC compared to CA50 also drastically increased the sensitivity in CRC. This was most clearly noticed in Dukes The increased tumour specificity of CA242 compared to CA50 found in the serological studies has also been demonstrated in several histological studies suggesting that there are differences in synthesis of the epitopes between benign and malignant tissues (Ouyang et al., 1987; Haglund et al., 1989) .
The monoclonal antibodies used in the CA50 and CA 19-9 assays have almost the same epitope specificity, the only difference being that the 19-9 MAb is specific for the sialylated Lewisa bloodgroup substance, whereas the C50 MAb also recognises sialylated lacto-N-tetraose (Magnani et al., 1982; Nilsson et al., 1985) . From the known epitope specificity of the antibodies used in the CA 19-9 and CA50 assays similar specificity and sensitivity should be expected in serological studies, and in agreement to CA50 an increased sensitivity of CA242 compared to CA 19-9 should be expected in CRC. This was also confirmed in this study.
In CRC, CEA has been the tumour marker of choice, and several studies have demonstrated the utility of detection of recurrent CRC (Minton et al., 1985; Minton & Chevinsky, 1989 markers which alone or in combination with CEA would increase the serological sensitivity for diagnosis and detection of recurrent CRC in patients where curative treatment would be possible if the diagnosis is available at an early stage, e.g. surgery of solitary liver metastases.
The results of this study show that although CEA gave higher sensitivity in CRC than CA242, the combined use of CEA and CA242 increased the diagnostic sensitivity considerably compared to the use of CEA alone (; 50% in Dukes A, -35% in Dukes B, t20% in Dukes C). The results also clearly demonstrate that CEA and CA242 were expressed independently of each other, which also indicates that CA242 could be a valuable complement to CEA in CRC.
This 
